Showing 7821-7830 of 8648 results for "".
- Rayner to Lower Carbon Footprint by More Than 800 Tons Over 5 Yearshttps://modernod.com/news/rayner-to-lower-carbon-footprint-by-more-than-800-tonnes-over-5-years/2478056/Rayner announced that changes to their manufacturing and packaging procedures will reduce CO2 greenhouse gas emissions by more than 800 tons over the next 5 years. The reduced CO2 greenhouse gas emissions are the result of three dedicated waste-reducing projects:
- Bausch + Lomb Introduces Pinnacle 360 25-Gauge Scleral Fixation Forcepshttps://modernod.com/news/bausch-lomb-introduces-pinnacle-360-25-gauge-scleral-fixation-forceps/2478053/Bausch + Lomb announced the introduction of the new Pinnacle 360 25-gauge Scleral Fixation Forceps. Bausch + Lomb will feature this innovation, as well as others in the company’s retina portfolio, during the virtual American Society of Retinal Specialists (ASRS) annual meeting, July 24-26, 2020.<
- Pfizer, BioNTech’s mRNA-Based COVID-19 Vaccine Shows Promise in Second Studyhttps://modernod.com/news/pfizer-biontechs-mrna-based-covid-19-vaccine-shows-promise-in-second-study/2478049/Pfizer and BioNTech announced that the most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralising titers after the second dose in an ongoing phase 1/2 study in Germany. The results, which were publ
- GenSight Biologics Reports Final REALITY Study Confirms Poor Spontaneous Recovery for LHON Patients with ND4 mutationhttps://modernod.com/news/gensight-biologics-reports-final-reality-study-confirms-poor-spontaneous-recovery-for-lhon-patients-with-nd4-mutation/2478050/GenSight Biologics reported results from the final analysis of the REALITY natural history study, which reaffirm the poor prognosis for the vast majority of Leber Hereditary Optic Neuropathy (LHON) patients with vision loss due to a mutated ND4mitochondrial gene. “The REALITY findings bols
- Synairgen’s Inhaled Interferon Beta Cuts Chance of Developing Severe COVID-19 Diseasehttps://modernod.com/news/synairgens-inhaled-interferon-beta-cuts-chance-of-developing-severe-covid-19-disease/2478043/Synairgen announced Monday that its inhaled formulation of interferon beta, dubbed SNG001, significantly reduced the chance of developing severe disease compared to placebo in hospitalized COVID-19 patients. Chief study investigator Tom Wilkinson remarked “the results confirm our belief tha
- House Telehealth Leaders Move to Cement Regulatory Changes for Virtual Carehttps://modernod.com/news/house-telehealth-leaders-move-to-cement-regulatory-changes-for-virtual-care/2478044/Leaders of the House telehealth caucus introduced legislation Thursday to permanently open up access to telehealth services for Medicare patients, according to a FierceHealthcare
- Trump Health Official Says COVID Patients Should Not Re-Test. ‘It’s clogging up the system.’https://modernod.com/news/trump-health-official-says-covid-patients-should-not-re-test-its-clogging-up-the-system/2478038/The Trump administration plans to release guidance that non-hospitalized patients who test positive for COVID-19 do not need a second test to confirm they are clear of the virus, according to a FierceHealthcare
- Interim 6-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosahttps://modernod.com/news/interim-6-month-data-of-rpgr-gene-therapy-shows-significant-vision-improvement-in-patients-living-with-x-linked-retinitis-pigmentosa/2478036/The Janssen Pharmaceutical Companies of Johnson & Johnson announced 6-month data from the ongoing phase 1/2 trial of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). The interim data showed that low and intermediate doses of
- Novartis to Provide 15 Drugs at Zero-Profit for Treating COVID-19 Symptomshttps://modernod.com/news/novartis-to-provide-15-drugs-at-zero-profit-for-treating-covid-19-symptoms/2478027/Novartis announced Thursday that 15 generic and over-the-counter medicines from its Sandoz unit will be made available at zero-profit to treat the major symptoms of COVID-19 in low-income and lower-middle-income countries. The drugs include those to treat gastro-intestinal illness, acute respirat
- Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucomahttps://modernod.com/news/nicox-reports-on-enrollment-progress-in-mont-blanc-phase-3-clinical-trial-in-glaucoma/2478024/Nicox SA announced that over 40 sites have been initiated in the first month of the phase 3 Mont Blanc trial, evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. NCX 470 is the company’s novel, second-generation nitric oxide (NO)-donating bimato